
Bruce F Bell
Examiner (ID: 17835)
| Most Active Art Unit | 1741 |
| Art Unit(s) | 1795, 1741, 1102, 1754, 2734, 1746, 1759, 1745 |
| Total Applications | 2788 |
| Issued Applications | 2338 |
| Pending Applications | 153 |
| Abandoned Applications | 297 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20349742
[patent_doc_number] => 20250346594
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-13
[patent_title] => GLP-1R Agonist and Therapeutic Method Thereof
[patent_app_type] => utility
[patent_app_number] => 19/271548
[patent_app_country] => US
[patent_app_date] => 2025-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29690
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19271548
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/271548 | GLP-1R Agonist and Therapeutic Method Thereof | Jul 15, 2025 | Pending |
Array
(
[id] => 20309144
[patent_doc_number] => 20250326773
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-23
[patent_title] => MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER
[patent_app_type] => utility
[patent_app_number] => 19/249435
[patent_app_country] => US
[patent_app_date] => 2025-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 128633
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19249435
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/249435 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | Jun 24, 2025 | Pending |
Array
(
[id] => 20232500
[patent_doc_number] => 20250289819
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-18
[patent_title] => CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 19/224601
[patent_app_country] => US
[patent_app_date] => 2025-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 113895
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 900
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19224601
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/224601 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | May 29, 2025 | Pending |
Array
(
[id] => 20219826
[patent_doc_number] => 20250282757
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-11
[patent_title] => ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS
[patent_app_type] => utility
[patent_app_number] => 19/218087
[patent_app_country] => US
[patent_app_date] => 2025-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59955
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19218087
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/218087 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | May 22, 2025 | Pending |
Array
(
[id] => 20150435
[patent_doc_number] => 20250250273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-07
[patent_title] => AZAINDOLE ROCK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 19/094486
[patent_app_country] => US
[patent_app_date] => 2025-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19094486
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/094486 | Azaindole rock inhibitors | Mar 27, 2025 | Issued |
Array
(
[id] => 20279339
[patent_doc_number] => 20250304581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-02
[patent_title] => INHIBITORS OF NLRP3 INFLAMMASOME
[patent_app_type] => utility
[patent_app_number] => 19/089839
[patent_app_country] => US
[patent_app_date] => 2025-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58028
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19089839
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/089839 | INHIBITORS OF NLRP3 INFLAMMASOME | Mar 24, 2025 | Pending |
Array
(
[id] => 20385409
[patent_doc_number] => 12485118
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-02
[patent_title] => Combinations of GLP-1R and THRb agonists and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 19/072846
[patent_app_country] => US
[patent_app_date] => 2025-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 34
[patent_no_of_words] => 44734
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 398
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19072846
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/072846 | COMBINATIONS OF GLP-1R AND THRss AGONISTS AND METHODS OF USE THEREOF | Mar 5, 2025 | Pending |
Array
(
[id] => 20068517
[patent_doc_number] => 20250206739
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-26
[patent_title] => Compounds
[patent_app_type] => utility
[patent_app_number] => 19/002520
[patent_app_country] => US
[patent_app_date] => 2024-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51763
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19002520
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/002520 | Compounds for activating a serotonin receptor | Dec 25, 2024 | Issued |
Array
(
[id] => 20271960
[patent_doc_number] => 12441729
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-14
[patent_title] => Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
[patent_app_type] => utility
[patent_app_number] => 18/987521
[patent_app_country] => US
[patent_app_date] => 2024-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7623
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18987521
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/987521 | Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | Dec 18, 2024 | Issued |
Array
(
[id] => 20329631
[patent_doc_number] => 12459896
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-04
[patent_title] => Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
[patent_app_type] => utility
[patent_app_number] => 18/988131
[patent_app_country] => US
[patent_app_date] => 2024-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 13800
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18988131
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/988131 | Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile | Dec 18, 2024 | Issued |
Array
(
[id] => 20239006
[patent_doc_number] => 12419308
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-23
[patent_title] => Phenylpyrazole insecticide compounds and compositions
[patent_app_type] => utility
[patent_app_number] => 18/959040
[patent_app_country] => US
[patent_app_date] => 2024-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18519
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18959040
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/959040 | Phenylpyrazole insecticide compounds and compositions | Nov 24, 2024 | Issued |
Array
(
[id] => 20024838
[patent_doc_number] => 20250163060
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-22
[patent_title] => SOLID FREEBASE FORMS OF 5-CHLORO-2-(4-((2-HYDROXY-2-METHYLPROPYL)AMINO)PYRIDO[3,4-D]PYRIDAZIN-1-YL)PHENOL FOR INHIBITING NLRP3 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/952401
[patent_app_country] => US
[patent_app_date] => 2024-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30250
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18952401
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/952401 | SOLID FREEBASE FORMS OF 5-CHLORO-2-(4-((2-HYDROXY-2-METHYLPROPYL)AMINO)PYRIDO[3,4-D]PYRIDAZIN-1-YL)PHENOL FOR INHIBITING NLRP3 AND USES THEREOF | Nov 18, 2024 | Pending |
Array
(
[id] => 20024836
[patent_doc_number] => 20250163058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-22
[patent_title] => MODULATORS OF DCN-1 AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/935253
[patent_app_country] => US
[patent_app_date] => 2024-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 112840
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18935253
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/935253 | Modulators of DCN-1 and methods of use thereof | Oct 31, 2024 | Issued |
Array
(
[id] => 20024835
[patent_doc_number] => 20250163057
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-22
[patent_title] => DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/935099
[patent_app_country] => US
[patent_app_date] => 2024-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 182432
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18935099
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/935099 | DCN-1 modulating compounds and methods of use thereof | Oct 31, 2024 | Issued |
Array
(
[id] => 19931704
[patent_doc_number] => 12304901
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => Selective ligands for tau aggregates
[patent_app_type] => utility
[patent_app_number] => 18/929263
[patent_app_country] => US
[patent_app_date] => 2024-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 11709
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18929263
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/929263 | Selective ligands for tau aggregates | Oct 27, 2024 | Issued |
Array
(
[id] => 19922923
[patent_doc_number] => 12297193
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => PTPN2/PTP1B degrader and therapeutic method thereof
[patent_app_type] => utility
[patent_app_number] => 18/918161
[patent_app_country] => US
[patent_app_date] => 2024-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 34392
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18918161
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/918161 | PTPN2/PTP1B degrader and therapeutic method thereof | Oct 16, 2024 | Issued |
Array
(
[id] => 19846687
[patent_doc_number] => 20250092038
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-20
[patent_title] => AZAINDOLE ROCK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/914975
[patent_app_country] => US
[patent_app_date] => 2024-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32023
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18914975
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/914975 | Azaindole rock inhibitors | Oct 13, 2024 | Issued |
Array
(
[id] => 19793307
[patent_doc_number] => 12234236
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-02-25
[patent_title] => GLP-1R agonist and therapeutic method thereof
[patent_app_type] => utility
[patent_app_number] => 18/884965
[patent_app_country] => US
[patent_app_date] => 2024-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32816
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18884965
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/884965 | GLP-1R agonist and therapeutic method thereof | Sep 12, 2024 | Issued |
Array
(
[id] => 19826271
[patent_doc_number] => 12247036
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-11
[patent_title] => Tricyclic compounds for the treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 18/812060
[patent_app_country] => US
[patent_app_date] => 2024-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 7
[patent_no_of_words] => 44967
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18812060
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/812060 | Tricyclic compounds for the treatment of cancer | Aug 21, 2024 | Issued |
Array
(
[id] => 19800427
[patent_doc_number] => 20250066352
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-27
[patent_title] => COMPOUNDS FOR FGFR INHIBITION
[patent_app_type] => utility
[patent_app_number] => 18/808641
[patent_app_country] => US
[patent_app_date] => 2024-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30264
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -66
[patent_words_short_claim] => 442
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18808641
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/808641 | Compounds for FGFR inhibition | Aug 18, 2024 | Issued |